Kala Pharmaceuticals Inc (KALA.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2017||Chairman of the Board, President, Chief Executive Officer|
|42||2017||Chief Financial Officer, Treasurer|
|47||2017||Chief Operating Officer|
|54||2017||Senior Vice President - Manufacturing and Supply Chain Management|
|47||2016||Senior Vice President - Regulatory Affairs and Quality Assurance|
- BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56
- BRIEF-Kala Pharmaceuticals submits new drug application for Inveltystm
- BRIEF-Kala Pharmaceuticals says on September 28, co increased size of board
- BRIEF-Wellington Management Group reports 11.84 pct passive stake in Kala Pharmaceuticals - SEC filing
- BRIEF-Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 pct passive stake in Kala Pharmaceuticals Inc